NYSE · ABT

Abbott Laboratories

Healthcare · Medical - Devices

$103.37▼ 1.77% ($1.86)at close

After hours$103.98▲ 0.59%7:51 PM ET

52-week

$81.97$137.49

Market cap

What the market price implies · Reverse DCF

To support a price of $103.37, this model requires revenue to grow by 6.85%/yr over the next 10 years, compounded annually.

Historical revenue grew by 0.72%/yr over the past 4 years. The required annual growth rate is 6.13 percentage points higher.

Selected forecast · Base scenario

3.91%/yr · actual 10-year annualized revenue growth

Year 1 growth: 6.11%

Market-implied · Base operating assumptions + edited margins

6.85%/yr · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Revenue & margin DCF

Price used

$103.37

Estimated value / share

$79.76

Base scenario

This estimate is 22.84% below the price used.

USD · TTM ending 2026-06-30

Year 1 growth 6.11% · Ending margin 17.03% · Discount rate 7.24%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 10, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 11, 2026, 2:07 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Only 1 consecutive positive FCFF years are available.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionModerate confidence

1Y Price: -20.1%Revenue (TTM): 8.06%FCF (TTM): 28.71%P/FCF: 5th pct

What changed

The stock fell 20.1% over the last year. Revenue grew 8.06% over the trailing twelve months. Operating margin moved from 17.51% to 17.03%. Free cash flow grew 28.71% over the trailing twelve months.

What the market seems to be pricing

Visible fundamentals weakened far less than the stock price, and the shares now sit around the 5th percentile of their historical P/FCF range. That looks more like a rerating of the multiple than a collapse in the business.

What would invalidate this read

This read changes if operating margin (currently 17.03%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.

Performance

Return analysis

Company profile

Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions.

CEORobert Ford

SectorHealthcare

IndustryMedical - Devices

Employees115,000

IPO dateMar 17, 1980

https://www.abbott.com

Market multiples

Forward P/E—

EV/EBITDA19.51

Enterprise value$225.43B

Stock splits

Jan 2, 2013↑ Forward

Every 2399 shares became 5000

+108%

May 3, 2004↑ Forward

Every 2339 shares became 2500

+7%

Jun 1, 1998↑ Forward

Every 1 shares became 2

+100%

Jun 1, 1992↑ Forward

Every 1 shares became 2

+100%

Jun 1, 1990↑ Forward

Every 1 shares became 2

+100%

Jun 2, 1986↑ Forward

Every 1 shares became 2

+100%

Jun 1, 1981↑ Forward

Every 1 shares became 2

+100%

May 23, 1978↑ Forward

Every 1 shares became 2

+100%

Profitability & growth

Revenue growth13.02%

Gross margin56.8%▲4.7ppvs FY2024

Operating margin17.03%▲1.9ppvs FY2024

ROE10.67%▼2.4ppvs FY2025

Analyst consensus

RatingBuy

Target price$123.64▲19.61%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Oct 21, 2026

Q4 FY26 · EPS est $1.43 · Revenue est $12.99B

View

Dividends

$2.48/shareQuarterlyDividend Achiever · 13yrAdequate

ABT pays a dividend with a 2.4% dividend yield, 13 consecutive years of growth, growing at 7.72% annually, covered 1.8× by free cash flow.

Dividend Yield

2.4%

Annual Div / Share

$2.48

5yr CAGR

+7.72%

Doubles every ~9.3yr

Payout Ratio

78.54%

Adequate

Dividend Growth Rate

3yr CAGR

+7.43%

5yr CAGR

+7.72%

10yr CAGR

+9.29%

Dividend Safety

6/10Adequate

Dividend History

Annualized dividend cycles per share

YearAnnual DivYoY

2026$2.48+6.9%

2025$2.32+7.4%

2024$2.16+8.0%

2023$2.00+7.5%

2022$1.86+8.8%

2021$1.71+22.1%

2020$1.40+12.9%

Income Projection

Invest

Growth rate:

Reinvest dividends

Today

$24/yr

$2/mo

In 5 yrs

$35/yr+45%

$3/mo

In 10 yrs

$50/yr+110%

$4/mo

Today	In 5 yrs	In 10 yrs
$24/yr $2/mo	$35/yr+45% $3/mo	$50/yr+110% $4/mo

Yield-on-cost grows from 2.4% → 5.05% over 10yr

Analysis

Dividend Strengths

Dividend Achiever

ABT has raised its dividend for 13 consecutive years — qualifying as a Dividend Achiever, demonstrating long-term commitment to shareholder income.

Well-covered by free cash flow

The dividend is covered 1.8× by free cash flow, indicating the company generates sufficient cash to sustain and potentially grow the payout without straining its finances.

Strong dividend growth rate

The 5-year CAGR of 7.72% meaningfully outpaces inflation, compounding real income growth for long-term holders.

Risks to Watch

No strong risk signal stands out from the latest period pair.

NYSE · ABT

Abbott Laboratories

Healthcare · Medical - Devices

$103.37▼ 1.77% ($1.86)at close

After hours$103.98▲ 0.59%7:51 PM ET

52-week

$81.97$137.49

Market cap

What the market price implies · Reverse DCF

To support a price of $103.37, this model requires revenue to grow by 6.85%/yr over the next 10 years, compounded annually.

Historical revenue grew by 0.72%/yr over the past 4 years. The required annual growth rate is 6.13 percentage points higher.

Selected forecast · Base scenario

3.91%/yr · actual 10-year annualized revenue growth

Year 1 growth: 6.11%

Market-implied · Base operating assumptions + edited margins

6.85%/yr · flat 10-year annualized revenue growth

Valuation

Recommended · Revenue & margin DCF

Price used

$103.37

Estimated value / share

$79.76

Base scenario

This estimate is 22.84% below the price used.

USD · TTM ending 2026-06-30

Year 1 growth 6.11% · Ending margin 17.03% · Discount rate 7.24%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 10, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 11, 2026, 2:07 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Only 1 consecutive positive FCFF years are available.

Price vs Fundamentals

Why The Stock Is Moving

Likely multiple compressionModerate confidence

1Y Price: -20.1%Revenue (TTM): 8.06%FCF (TTM): 28.71%P/FCF: 5th pct

What changed

The stock fell 20.1% over the last year. Revenue grew 8.06% over the trailing twelve months. Operating margin moved from 17.51% to 17.03%. Free cash flow grew 28.71% over the trailing twelve months.

What the market seems to be pricing

What would invalidate this read

This read changes if operating margin (currently 17.03%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.

Performance

Return analysis

Company profile

CEORobert Ford

SectorHealthcare

IndustryMedical - Devices

Employees115,000

IPO dateMar 17, 1980

https://www.abbott.com

Market multiples

Forward P/E—

EV/EBITDA19.51

Enterprise value$225.43B

Stock splits

Jan 2, 2013↑ Forward

Every 2399 shares became 5000

+108%

May 3, 2004↑ Forward

Every 2339 shares became 2500

+7%

Jun 1, 1998↑ Forward

Every 1 shares became 2

+100%

Jun 1, 1992↑ Forward

Every 1 shares became 2

+100%

Jun 1, 1990↑ Forward

Every 1 shares became 2

+100%

Jun 2, 1986↑ Forward

Every 1 shares became 2

+100%

Jun 1, 1981↑ Forward

Every 1 shares became 2

+100%

May 23, 1978↑ Forward

Every 1 shares became 2

+100%

Profitability & growth

Revenue growth13.02%

Gross margin56.8%▲4.7ppvs FY2024

Operating margin17.03%▲1.9ppvs FY2024

ROE10.67%▼2.4ppvs FY2025

Analyst consensus

RatingBuy

Target price$123.64▲19.61%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Oct 21, 2026

Q4 FY26 · EPS est $1.43 · Revenue est $12.99B

View

Dividends

$2.48/shareQuarterlyDividend Achiever · 13yrAdequate

ABT pays a dividend with a 2.4% dividend yield, 13 consecutive years of growth, growing at 7.72% annually, covered 1.8× by free cash flow.

Dividend Yield

2.4%

Annual Div / Share

$2.48

5yr CAGR

+7.72%

Doubles every ~9.3yr

Payout Ratio

78.54%

Adequate

Dividend Growth Rate

3yr CAGR

+7.43%

5yr CAGR

+7.72%

10yr CAGR

+9.29%

Dividend Safety

6/10Adequate

Dividend History

Annualized dividend cycles per share

YearAnnual DivYoY

2026$2.48+6.9%

2025$2.32+7.4%

2024$2.16+8.0%

2023$2.00+7.5%

2022$1.86+8.8%

2021$1.71+22.1%

2020$1.40+12.9%

Income Projection

Invest

Growth rate:

Reinvest dividends

Today

$24/yr

$2/mo

In 5 yrs

$35/yr+45%

$3/mo

In 10 yrs

$50/yr+110%

$4/mo

Today	In 5 yrs	In 10 yrs
$24/yr $2/mo	$35/yr+45% $3/mo	$50/yr+110% $4/mo

Yield-on-cost grows from 2.4% → 5.05% over 10yr

Analysis

Dividend Strengths

Dividend Achiever

ABT has raised its dividend for 13 consecutive years — qualifying as a Dividend Achiever, demonstrating long-term commitment to shareholder income.

Well-covered by free cash flow

The dividend is covered 1.8× by free cash flow, indicating the company generates sufficient cash to sustain and potentially grow the payout without straining its finances.

Strong dividend growth rate

The 5-year CAGR of 7.72% meaningfully outpaces inflation, compounding real income growth for long-term holders.

Risks to Watch

No strong risk signal stands out from the latest period pair.